YCYitian Chen

Yitian Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Yitian Chen has a total of 64 co-authors. Here are the top co-authors by number of shared publications:

  • Xiaoyuan Chu

    Jinling Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, China

    6 shared publications
  • Zengjie Lei

    Department of Medical Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210000, China

    4 shared publications
  • Dan Xiang

    Department of Medical Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China

    3 shared publications
  • Zhaochen Sun

    Department of Medical Oncology, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu 210018, P.R. China

    3 shared publications
  • Chao Liu

    Department of Medical Oncology, Jinling Hospital, Nanjing Clinical School of Nanjing Medical University, Nanjing, China

    2 shared publications
  • Dong Han

    Department of Medical Oncology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    2 shared publications

Latest Publications

  • Open Access

    Tislelizumab‑induced psoriasis in a patient with hepatocellular carcinoma: A case report

    by Zhaochen Sun, Yuqi Zhou, Yeliang Mei, Yitian Chen

    Immune checkpoint inhibitors (ICIs) are widely incorporated into first‑line treatment regimens for advanced hepatocellular carcinoma (HCC). Nevertheless, the growing incidence of immune‑related adverse events (irAEs), particularly dermatologic toxicities, poses a substantial challenge to the continuation of anticancer therapy. The present study describes a case of tislelizumab‑associated psoriasis in a patient with hepatitis C virus (HCV)‑related HCC, emphasizing the need for prompt recognition and individualized management. A 60‑year‑old man with stage IIIA HCC and chronic HCV infection developed progressively worsening erythematous plaques with scaling during the eighth cycle of tislelizumab plus bevacizumab. Histopathological examination of a skin biopsy supported a diagnosis of pustular psoriasis. A Naranjo Adverse Drug Reaction Probability Scale score of 7 suggested that tislelizumab was the probable causative agent. Because the patient had type 2 diabetes mellitus and declined systemic glucocorticoid treatment, tislelizumab was discontinued, and narrow‑band ultraviolet B (NB‑UVB) phototherapy was administered in combination with topical corticosteroids. The skin lesions markedly resolved with no recurrence during the 6‑week follow‑up period. To the best of our knowledge, this is the first report of NB‑UVB phototherapy successfully treating ICI‑induced psoriasis. This case underscores the need for close monitoring of cutaneous irAEs during ICI therapy and suggests that NB‑UVB phototherapy may be an effective alternative to systemic corticosteroids for managing ICI‑induced psoriasis, particularly in patients where preservation of antitumor immunity is desirable or systemic steroids are contraindicated. Regular multidisciplinary follow‑up and individualized management of adverse events are essential for optimizing both oncological and dermatological outcomes.


  • Open Access

    SMYD3 synergises with RACK1 to promote colorectal cancer lung metastasis by recruiting SMAD3

    by Xiaoming Bai, Dong Han, Jie Chen, Siqi Sheng, Haimei Feng, Hongyu Wang, Ke Xu, Yadi Huang, Mengxi Huang, Xiaoyuan Chu, et al.

    Cancer metastasis is the leading cause of mortality associated with cancer, and the prognosis for patients diagnosed with colorectal cancer(CRC) largely depends on the occurrence of metastasis during the progression of the disease. A comprehensive understanding of the mechanisms underlying metastasis in CRC is essential for advancing treatment strategies. Through integrated bioinformatics analysis of mRNA expression profiles and epigenetic modifiers, we identified SMYD3 as the top differentially expressed histone modifier in CRC. Clinically, SMYD3 overexpression significantly associates with poor prognosis and enhances metastatic potential. Utilizing immunoprecipitation-mass spectrometry, we discovered RACK1 as a novel SMYD3-interacting protein. Subsequent mechanistic studies revealed a tripartite interaction network: SMYD3 recruits SMAD3 through RACK1-mediated scaffolding, facilitating transcriptional activation of the downstream effector TSKU. Notably, RACK1 depletion disrupts SMYD3-SMAD3 complex formation, establishing the critical role of this axis in metastasis regulation. Consequently, inhibiting the SMYD3-SMAD3 interaction may represent a promising therapeutic strategy for addressing CRC metastasis. In conclusion, targeting the SMYD3-RACK1-SMAD3 transcriptional complex presents a viable approach for the treatment of CRC metastasis.

  • Open Access

    Prognostic factors affecting survival in patients with duodenal adenocarcinoma and isolated liver metastases: a retrospective study

    by Jun Pan, Jie Li, Ying Chen, Yitian Chen, Xiaoyuan Chu

    The study aimed to identify the prognostic factors affecting survival among patients with duodenal adenocarcinoma (DAC) and isolated hepatic metastases (HM). We conducted a retrospective analysis of clinical data from 51 patients treated for DAC and HM from January 2012 to January 2018. The Kaplan-Meier method and log-rank test were used for survival analysis. The Cox proportional hazards regression model was utilized for multivariate analysis. Thirty-nine patients had synchronous HM, and 12 patients exhibited metachronous HM. Median overall survival (mOS) for patients with synchronous HM was 6.8 months, versus 45.9 months for those with metachronous HM (P < 0.001). mOS for the patients who received first-line chemotherapy was 18.9 months, compared with 4.4 months for the patients who did not undergo first-line chemotherapy (P < 0.001). Multivariate analysis identified the timing of HM detection and the receipt of first-line chemotherapy as independent prognostic factors. Subgroup analysis revealed that among patients with synchronous HM, mOS for patients who underwent primary tumor resection was 16.9 months, compared with 3.5 months for those who did not undergo resection (P < 0.001). The timing of detection of HM and the receipt of first-line chemotherapy are independent prognostic factors for patients with DAC and isolated HM.

  • Open Access

    Case report: successful response to bevacizumab combined with erlotinib for a novel FH gene mutation hereditary leiomyoma and renal cell carcinoma

    by Xiaoming Bai, Dan Xiang, Mengxi Huang, Yitian Chen

    FH-deficient Renal Cell Carcinoma (FH-deficient RCC) are inherited tumors caused by mutations in the fumarate hydratase (FH) gene, which plays a role in the tricarboxylic acid cycle. These mutations often result in aggressive forms of renal cell carcinoma (RCC) and other tumors. Here, we present a case of FH-deficient RCC in a 43-year-old woman with a history of uterine fibroids. She exhibited a new heterozygous mutation in exon six of the FH gene (c.799_803del, c.781_796del). The patient had multiple bone metastases and small subcutaneous nodules in various areas such as the shoulders, back, and buttocks. Biopsy of a subcutaneous nodule on the right side revealed positive expression of 2-succinate-cysteine (2SC), and FH staining indicated FH expression deletion. The patient underwent treatment with a combination of erlotinib and bevacizumab, which resulted in significant efficacy with moderate side effects. This treatment combination may be recommended as a standard regimen. This case underscores the importance of genetic testing in patients with advanced renal cancer to enhance diagnostic accuracy. Furthermore, it provides insights into potential treatment approaches for FH-deficient RCC.


  • Open Access

    Case report: Concurrent intrathecal and intravenous pembrolizumab for metastatic melanoma with leptomeningeal disease

    by Xiang Dan, Mengxi Huang, Zhaochen Sun, Xiaoyuan Chu, Xin Shi, Yitian Chen

    Leptomeningeal disease (LMD) is a serious cancer complication associated with poor prognosis. Approximately 5%–25% of patients with melanoma develop LMD. Currently, no standard treatment protocol exists and very few cases have been reported. Despite ongoing advances in new therapies, treatment options for LMD remain limited. Herein, we report a case of intrathecal pembrolizumab administration in a patient with melanoma and LMD. Intrathecal pembrolizumab administration was feasible and safe at the doses tested. Drawing from this case, along with our expertise and the existing evidence on systemic immunotherapy, we propose that an immunotherapy approach involving intrathecal administration for patients with LMD from melanoma warrants additional exploration in clinical trials.


  • Open Access

    Survival analysis and prognostic model establishment of secondary osteosarcoma: a SEER-based study

    by Jing Wang, Gongbo Fu, Zhongxiu Bd Zhu, Lan Bd Ding, Yitian Chen, Huiyu Bd Li, Dan Xiang, Zhe Dai, Jialong Zhu, Linlin Ji, et al.

    Background: Surgical excision is considered one of the most effective treatments for secondary osteosarcoma (SO). It remains unclear whether the survival of patients with secondary osteosarcoma (SO) could be associated with their surgical willingness. Materials and methods: The statistics of the patients diagnosed with SO between 1975 and 2008 were gathered from the surveillance epidemiology and end results (SEER) database. The patients were divided into three subgroups according to their surgical compliance. The authors used the multivariable Logistic regression analysis and cox regression method to reveal the influence of surgical compliance on prognosis and the risk factors of surgical compliance. Additionally, the authors formulated a nomogram model to predict the overall survival (OS) of patients. The concordance index (C-index) was used to evaluate the accuracy and practicability of the above prediction model. Results: Sixty-three (9.2%) of the 688 patients with SO who were recommended for surgical treatment refused to undergo surgery. Lower surgical compliance can be ascribed to an earlier time of diagnosis and refusal of chemotherapy. The lower overall survival (OS) {[hazard ratio (HR)] 1.733, [CI] 1.205-2.494, P value [P]=0.003} of not surgical compliant patients was verified by the multivariate cox regression method, compared with surgical compliant patients. In addition, the discernibility of the nomogram model was proven to be relatively high (C-index=0.748), by which we can calibrate 3-year- and 5-year OS prediction plots to obtain good concordance to the actual situation. Conclusions: Surgical compliance was proved to be an independent prognostic factor in the survival of patients with SO.


  • Open Access

    Cervical cancer heart metastasis presents as a giant mass

    by Zhaochen Sun, Dan Xiang, Junyan Jiang, Song Luo, Yitian Chen

    A 40-year-old female patient has been diagnosed with Stage IVB cervical squamous cell carcinoma, with no previous history of heart disease. She had undergone chemotherapy with six cycles of liposome paclitaxel and nedaplatin and radiation therapy (45GY/25F) for the treatment of systemic metastases involving the abdominal lymph nodes, lungs, pubic bone, and iliac bone. On admission, the patient exhibited sudden onset dyspnoea. Her pulse oximetry was 92% (oxygen flow; 2–3 L/min), troponin I was 8.17 ng/mL (normal Panels A and B). Cardiac magnetic resonance (CMR) imaging confirms the presence of a tumour measuring 5 × 4 × 2 cm in the RV cavity, along with a small amount of pericardial effusion signal. The T1 sequence of the CMR black blood sequence shows a homogeneous signal that almost fills the RV (Panel C). The cine sequence indicates that the ventricular mass fluctuates with the heartbeat, infiltrates the myocardium, and extends towards the outflow tract of the RV (see Supplementary material online , Videos S1 and S2). Late gadolinium enhancement sequence shows an inhomogeneous signal in the mass, suggesting a neoplastic lesion (Panel D). Treatment with subcutaneous enoxaparin sodium (4000 AxalU bid) proved ineffective. The patient ultimately underwent RV tumour resection. Intra-operatively, a fish-like mass was found in the RV (Panel E). Post-operative pathological examination confirmed it as a metastatic lesion of cervical cancer (Panel F).

  • Open Access

    Cardiac Metastasis from Cervical Cancer: A Case Report and literature review

    by Zhaochen Sun, Yitian Chen

    Heart metastasis in cervical cancer is an exceptionally uncommon occurrence. Given the early onset of obscure clinical presentations and complex imaging features of cardiac tumors, cases diagnosed before death are exceedingly rare. In this report, we present a case of cervical cancer with cardiac tumor metastasis diagnosed pre-mortem, and conducted a review of the current literature. The following conclusions were drawn: (1) The incidence of cardiac metastasis is influenced by clinical stage and treatment modality at initial diagnosis. (2) The prognosis for patients with cervical cancer heart metastasis is poor, and those with severe complications struggle to accrue benefits from active treatment. (3) When cervical cancer patients present with unexplained dyspnea, cardiac color ultrasound and enhanced chest CT should be performed to rule out tumor cardiac metastasis.

  • Open Access

    Case report: POLE (P286R) mutation in a case of recurrent intestinal leakage and its treatment

    by Dang Xiang, Gongbo Fu, Yitian Chen, Xiaoyuan Chu

    In recent years, although new drugs and molecular markers have been used to treat metastatic colorectal cancer, there has been little progress in the immunotherapy of advanced colon cancer. The development of sequencing and multiomics technology helps us classify patients more accurately, and then find patients who may benefit from immunotherapy. The development of this advanced technology and immunotherapy based on new targets may herald a new era in the treatment of metastatic colorectal cancer. It is well known that colorectal cancer with dmmr/msi-h phenotype is sensitive to immunotherapy, yet the POLE mutation is the MSS phenotype in colorectal tumors but is also an effective target for immunotherapy. This paper describes a case of recurrent intestinal leakage that required multiple surgical procedures. A high-grade colon adenocarcinoma was identified on surgical histopathology after 18 months, and bevacizumab combined with oxaliplatin and capecitabine proved ineffective against this cancer. An analysis of gene expression indicated that POLE (P286R) mutation, TMB 119.333 mutation per 100 MB, and immune checkpoint inhibitor treatment had a significant impact. This case reminds us that the existence of malignant tumors should be considered for patients with repeated intestinal leakage, and emphasizes the importance of gene detection in the treatment of malignant tumors and the significance of POLE mutations in colorectal cancer.


  • Open Access

    The Circumferential Resection Margin Is a Prognostic Predictor in Colon Cancer

    by Xin-Yi Tang, Meng-Xi Huang, Si-Qi Han, Yue Chang, Zhi-Ping Li, Xiao-Ming Kao, Yan-Yan Chen, Chao Liu, Ya-Di Huang, Yi-Tian Chen, et al.

    Objective: This study aimed to investigate the potential value of circumferential resection margin (CRM) in colon cancer prognostics. Summary Background Data: CRM has been extensively studied as an important prognostic factor in rectal and esophageal cancer, but not in colon cancer. Methods: Data from 6,681 CRM-positive patients and 25,908 CRM-negative patients diagnosed with colon cancer in 2010–2015 were obtained from the Surveillance, Epidemiology, and End Results database. Statistical analysis methods utilized included the chi-square test, Kaplan-Meier estimates, Cox proportional, and X-tile software analyses. Results: After propensity score matching, CRM positivity was found to be negatively related with survival (P < 0.001). X-tile software identified 0 and 30 mm as optimal cutoff values (P < 0.001) for prognosis, which was applicable only in stage II–IV patients. A 20 and 33% risk decrease were observed in patients with CRM between 0 and 30 mm [95% confidence interval (CI) = 0.76–0.84], and larger than 30 mm (95% CI = 0.62–0.71), respectively. Chemotherapy strongly benefited prognosis with a hazard ratio of 0.36 (95% CI = 0.34–0.38) for overall survival (OS). Patients with a CRM value of 0–30 mm seemed to benefit most from chemotherapy compared with other groups. CRM and number of regional lymph nodes are independent risk factors, and the latter is a good substitute for CRM in AJCC stage I patients. Conclusion: CRM positivity is a strong unfavorable survival indicator for colon cancer patients. A better outcome is expected with CRM values larger than 30 mm. This cutoff value only applied to stage II–IV patients. For stage I patients, number of regional lymph nodes is a good substitute to predict survival. Chemotherapy was another favorable prognostic factor, especially for patients with a CRM value between 0 and 30 mm.